Lasa Supergenerics growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue−82.4%−42.1%
Total Assets−34.7%−26.0%
Total Equity−40.7%−25.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

LASA₹4.67

Lasa Supergenerics Limited

· Pharma & Health
₹ CrorePeersMANGALAMBIOFILCHEMORTINGLOBEVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹23.4 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue-82.4-42.1
Total Assets-34.7-26.0
Total Equity-40.7-25.1
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.